The scrutiny follows the July 22, 2026, disclosure of fiscal 2027 first-quarter results, where the company reported earnings per share of just $0.06. This performance was dragged down by a ₹2.4 billion provision linked to out-of-specification semaglutide batches. CEO Erez Israeli attributed the thin EBITDA margins to a combination of production losses, rejected inventory, and reduced sales incentives. Following the announcement, share prices slid $1.18 to close at $11.38. Investors who held stock during this period are now being encouraged to contact the firm to discuss potential class action participation.
Pomerantz LLP Launches Inquiry into Dr. Reddy’s Laboratories
A 9.4% drop in stock value following a disappointing quarterly earnings report has triggered a formal investigation by Pomerantz LLP into Dr. Reddy’s Laboratories. The New York-based law firm is examining potential securities fraud and unlawful business practices involving the company's executive leadership and board of directors.
Comments (0)
No comments yet. Be the first!